Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.09.10
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patie ...
PDF (348 KB)
2019.09.10
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at ...
PDF (188 KB)
2019.09.09
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...
PDF (261 KB)
2019.08.21
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...
PDF (297 KB)
2019.08.12
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
PDF (151 KB)
2019.08.02
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGC ...
PDF (368 KB)
2019.06.21
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Rela ...
PDF (206 KB)
2019.06.18
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory <i>F ...
PDF (153 KB)
2019.06.02
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with N ...
PDF (193 KB)
2019.06.01
Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosyno ...
PDF (244 KB)
Showing 1 - 10 of 46 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...